skip to content »

Translational Biology & Molecular Medicine

Houston, Texas

Benchtop, Research, Bedside and Application
Translational Biology & Molecular Medicine Graduate Program
not shown on screen

Vijay Nambi, M.D.

Vijay Nambi, M.D.Assistant Professor
Department of Medicine - Atherosclerosis and Vascular Medicine

Phone: 713-798-7545
Fax: 713-798-4121
E-mail: vnambi@bcm.edu

Education

  • M.B.B.S., Madras (Chennai) Medical College, Chennai, India
  • Residency, Internal Medicine, Cleveland Clinic Foundation
  • Fellowship, Vascular Medicine, Cleveland Clinic Foundation
  • Fellowship, Cardiovascular Medicine, Baylor College of Medicine

Research Interests

  • Atherosclerosis imaging
  • Cardiovascular disease, prevention and risk prediction
  • Biomarkers

Clinical Focus

  • Lipids
  • Preventive cardiology
  • Vascular medicine

Selected Publications

  • Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, Volcik K, Boerwinkle E, Ballantyne CM. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010. 55(15):1600-7.
  • Nambi V, Hoogeveen RC, Chambless L, Hu Y, Bang H, Coresh J, Ni H, Boerwinkle E, Mosley T, Sharrett R, Folsom AR, Ballantyne CM. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009. 40(2):376-81.
  • Nambi V, Kimball KT, Bray PF, Bergeron AL, Johnson SL, Morrisett JD, Chen C, Lin PH, Lumsden AB, Ballantyne CM, Dong JF. Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets. 2009. 20(3):199-205.
  • Yang EY, Nambi V, Tang Z, Virani SS, Boerwinkle E, Hoogeveen RC, Astor BC, Mosley TH, Coresh J, Chambless L, Ballantyne CM. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009. 54(25):2388-95.
  • Nambi V, Morrison AC, Hoogeveen RC, Coresh J, Miles S, Rhodes CE, Sharrett AR, Boerwinkle BE, Ballantyne CM. Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. Tex Heart Inst J. 2008. 35(4):388-94.
  • Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003. 349(17):1595-604.

E-mail this page to a friend